Lantern Pharma (LTRN) Long-Term Deferred Tax (2019 - 2026)

Lantern Pharma's (LTRN) quarterly Long-Term Deferred Tax came in at $54827.0 in Q1 2026, down 38.0% on a QoQ basis from $88431.0 in Q4 2025.

Lantern Pharma (LTRN) Long-Term Deferred Tax (2019 - 2026) Analysis & Trends

Lantern Pharma (LTRN) has 5 years of Long-Term Deferred Tax data on file, last reported at $54827.0 in Q1 2026.

Quarterly Long-Term Deferred Tax changed N/A year-over-year to $54827.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $54827.0 (changed N/A YoY) and the FY2025 annual result came in at $88431.0, changed N/A from the prior year.
Long-Term Deferred Tax declined to $54827.0 in Q1 2026, from $88431.0 in the prior quarter.
In the past five years, Long-Term Deferred Tax ranged from a high of $88431.0 in Q4 2025 to a low of $54827.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Lantern Pharma	26.05 Mn	26.05 Mn	-

Download Data